Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (September 2023)
29 slides from Matinas Biopharma's investor presentation, Sep 20, 2023
Slide 1: Corporate Presentation September/October 2023
MATINAS BIOPHARMA Corporate Presentation September/ October 2023 www.matinasbiopharma.com NYSE American: MTNB
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value
Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value i > Intracellular delivery Lipid Nanocrystals > Oral administration > Less toxicity (LNCs) > Targeting beyond the liver MAT2203 Clinical Validation Pipeline Products of LNC Capabilities and Opportunities we > @ * Oral Amphotericin B -
Slide 4: Internal and External Pipeline
Internal and External Pipeline Program Indication Discovery Preclinical Phase 1 Phase 3 Collaborators MAT2203 Invasive Aspergillosis LNC-AmphotericinB_——_(LPAD) Phase 3 Ready (oral) LNC Internal ky Unelsclosed (mall oligonucleotides) LNC-small molecule undisclosed LZ!» Genentech ‘ener of i Race Gp L
Slide 5: Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform
Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Delivery of small molecules and small oligonucleotides 3 ys 333 E fe » Successful delivery of small molecules, proteins, small oligos ie (siRNA, ASOs), and vaccines Extra-hepatic targeting i © Selective uptake driven b
Slide 6: Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery
Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery Targeting Stressed Cells Externalize PS Normally, PS is confined to ‘the inner layer (facing cytosol) With injury, PS moves from the inner layer to the outer layer of the cell membrane CELL MEMBRANE (CYTOSOL CELL MEMBRAN PHOSPH
Slide 7: LNCs - Differentiated from Liposomes and LNPs
LNCs - Differentiated from Liposomes and LNPs 5f- Structure ° Formulation Strengths @® Formulation Limitations Liposome * Aqueous interior surrounded by bilayer + Drug can be encapsulated in aqueous core or bilayer + Enable IV administration of insoluble products + Liposomes often “leak” causing sid
Slide 8: MAT2203
MAT2203 Oral Amphotericin B Clinical Validation of LNC Delivery MATINAS
Slide 9: The Growing Threat of Invasive Fungal Infections (IFIs)
The Growing Threat of Invasive Fungal Infections (IFls) WIRED Nature Reviews Microbiology 2022 ‘Te Battle Against the Fungal Apocalypse I= ust Beginning WHO fungal priority pathogens list to guide research, development and health action Tackling the emerging threat of antifungal resistance to human
Slide 10: MAT2203: Unlocking the Full Potential of Amphotericin B
0 MAT2203: Unlocking the Full Potential of Amphotericin B Innate Amphotericin B lV Amphotericin B — Unlocked Characteristics Limitations — Potential POTENT - Only available through Available systemically Y 1) 1) © broad-spectrum fungicidal Minimal drug-drug interactions Low propensity for resistance
Slide 11: EnACT: Phase 2 Clinical Validation of Safety and Efficacy
" EnACT: Phase 2 Clinical Validation of Safety and Efficacy EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity Exceeded the primary All patients completing No breakthrough Survival at Day 30 MAT2203 was safe and en
Slide 12: Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal
Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal Clinical Infectious Diseases Ve! a h Ivma Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial David R. Boulware," Mucunguzi Atukunda,* Enock Kagimu,” Abdu K. Musubire,? Andrew Akampurira,’
Slide 13: MAT2203 Expanded Access Program - Targeted Treatment of IFIs Throughout the Body
MAT2203 Expanded Access Program - Targeted Treatment of IFls Throughout the Body Sinus Mucor nidicola Pansinusitis Lung Aspergillus calidoustus Pulmonary aspergillosis Probable fusarium species Fusarium pneumonia Skin Prototheca wickerhamii Fusarium falciforme Skin infection Skin graft Fusarium spec
Slide 14: MAT2203 Expanded Access/Compassionate Use Program
“ MAT2203 Expanded Access/Compassionate Use Program Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options * 11 patients with no other treatment options are currently receiving or have completed treatment with MAT2203 — Notable Healthcare Institutions: NIH, University of Michi
Slide 15: High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)
High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA) * Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients = ~15,000 new cases per
Slide 16: MAT2203 Regulatory Strategy
6 MAT2203 Regulatory Strategy * Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole) — Register leveraging LPAD pathway
Slide 17: Proposed Phase 3 Study Design in IA
Proposed Phase 3 Study Design in IA To assess the efficacy and safety of MAT2203 in patients with Invasive Aspergillosis (IA) in adults who have limited or no alternative treatment. options following initial intravenous treatment Patients will be randomized 2:1 to receive either oral MAT2203 as “ste
Slide 18: MAT2203 Value Proposition
MAT2203 Value Proposition ORAL LACK OF AMPHOTERICIN B ADMINISTRATION NEPHROTOXICITY with a potent fungicidal ager Phase 2 X LCM Meningitis e 4 Treatment of Other IFIs (Proof of Concept) ts) 4 + Prophylaxis Near-Term Development Strategy: Focused strategy on Phase 3 registration trial in Invasive Asp
Slide 19: LNCs Beyond MAT2203
LNCs Beyond MAT2203 Efficient and Safe Delivery of Small Oligos COPYRIGHT MATINAS BIOPHARMA - 2023 MATINAS
Slide 20: LNC Experience to Date
LNC Experience to Date 20 Animal model Molecule Cargo Indication (ystic fibrosis mouse model Amikacin Mucocutaneous ASO candidiasis ‘Amphotericin - B BALB/c mouse flumodel Flu protein Job's syndrome, NIH IRNA Bo eee Srae5 Amphotericin -B Infection Mouse SARS-CoV-2 model Remdesivir HIV / cryptococcal
Slide 21: LNC-Remdesivir: In vivo Efficacy Against SARS-CoV-2
LNC-Remdesivir: /7 vivo Efficacy Against SARS-CoV-2 @ cited In Mice Infected With Sars-COV-2, Oral LNC-Remdesivir Mitigated Weight Loss, Improved Congestion Scores, and Reduced Viral Lung Titers (Beginning On Day 2) 110 5 10° 2 4 ge é 3 100 2 ee 2 wo a = 3 2 2 e3 @ ee § 10° zo 2 3 z 8 G2 © @ 5 o 8 0
Slide 22: LNCs are Taken up by Blood Cells - Human Whole Blood Flow Cytometry
Neutrophils Monocytes mpc LNCs are Taken up by Blood Cells — Human Whole Blood Flow Cytometry (3 hrs incubation with labeled LNCs) Baseline [lUnstim % Cellular Uptake 93.8 Neutrophils Monocytes Innate Cells 7 7 : 4.4 mDC ppc Baseline 3hrs Sf Unstim Lymphocytes 69.7 = 2 | = ees = cpa+ cps+ B Cells NK
Slide 23: In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations
/n vitroTumor Cell Inhibition with LNC Docetaxel Formulations 3 LNC Formulations Demonstrated Significantly Better Tumor Cell Inhibition Than Unformulated Drug efficacy in inhibiting tumor cell growth * In vivo studies planned in multiple RATIONALE AND NEXT STEPS -MMS1 -S-MMS3 —e-MMS4 — —>-Taxol * L
Slide 24: In vitro Dose-Dependent Knockdown of IL-17A in Murine T Cells
/n vitro Dose-Dependent Knockdown of IL-17A in Murine T Cells STUDY DESIGN LNC Formulation of an RNAi Small oligo: 18-25 nucleotides EL4 cells: 200k/well IL-6 (0.3 ug/ml) stimulation Treat and evaluate @ 24 hrs looking at IL-17 protein production IL-17A (pg/ml) KEY RESULTS IL-17 Knockdown ILNC Formu
Slide 25: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics FUTURE I UNDER EVALUATION Potential Therapeutic Applications INFECTION IMMUNE RX PROVEN © Anti-infectives » Vaccines » Antivirals » Immune tolerance
Slide 26: Rapid Evolution of Platform Sets Stage for Active Q4
Rapid Evolution of Platform Sets Stage for Active Q4 4.2022 Q1.2023 Q2 2023 Q3 2023 Q4 2023 neral Expended Access Pipeline Presentation and Potential Expanded Access ENACT case presentations ENACT publication Late Breaker Oral Abstract Infection presentation (ID week October 2023) LNG uptake by Biol
Slide 27: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity i, MAT2203 potentially Global Platform IP Recent patent entitled to 12+ years base protection out to applications based on of exclusivity 2037 with 20 patents formulation wor
Slide 28: Experienced Leadership Team
Experienced Leadership Team EXECUTIVE TEAM Thomas Hoover, MBA Chief Business Officer Jerome D. Jabbour, J.D. Chief Executive Officer ‘Theresa Matkovits, Ph.D. Chief Development Officer SEMILLENDO *8sunovion G@Rettant® oS nps U Novartis Corea \) Hui Liu, Ph.D., MBA Chief Technology Officer James Ferg
Slide 29: Matinas Investment Thesis
Matinas Investment Thesis Financial Summary Runway into Sept. 2024 $22.5M! in Cash, Cash Equivalents and Marketable Securities aso 06/30/23 © Non-Dilutive Financing Options ge Near-Term Milestones- Setup for Strong Close to 2023 Q4 - FDA Meeting and Feedback on MAT2203 Phase 3 Invasive Aspergillosis
Matinas BioPharma Holdings — Investor Presentation (September 2023) on 6ix